Latest articles
What’s been authorised? UK, Europe, US drug approvals
Pf summarises the UK, Europe and US drug approvals from 20 - 24 Jan 2020. UK The National Institute for Health and Care Excellence published draft...
Digital interventions for behaviour change
New NICE guidance looks at digital interventions for behaviour change and suggests that these interventions such as apps, wearable devices and online programmes and...
Acute aortic dissection is a ‘ticking time bomb’
Safety body calls for earlier recognition of ‘ticking time bomb’ aortic dissection to prevent deaths as its new report reveals that up to half...
Popular articles
NICE rejects Janssen’s Stelara for moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has not recommended ustekinumab, Janssen's Stelara, for treating moderately to severely active ulcerative colitis in...
Meningitis B infant vaccination programme shows 75% drop in cases over three years
Meningitis B infant vaccination programme shows 75% drop in cases over three years, these are the results of one of two independent meningitis B...
AstraZeneca’s Tagrisso▼ (osimertinib) rejected by NICE for use in NHS England
The National Institute for Health and Care Excellence (NICE) has published final guidance that does not recommend AstraZeneca's Tagrisso▼ (osimertinib) for use within NHS...
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Integrated commercial deployment in life sciences and other 2020 health trends
Syneos Health explore integrated commercial deployment in life sciences and discuss their new report covering 2020 health trends. Life science leaders aren’t launching with...